Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). METHODS: This first-in-human trial (ClinicalTrials.gov identifier: NCT02500407...

Descripción completa

Detalles Bibliográficos
Autores principales: Budde, Lihua E., Assouline, Sarit, Sehn, Laurie H., Schuster, Stephen J., Yoon, Sung-Soo, Yoon, Dok Hyun, Matasar, Matthew J., Bosch, Francesc, Kim, Won Seog, Nastoupil, Loretta J., Flinn, Ian W., Shadman, Mazyar, Diefenbach, Catherine, O'Hear, Carol, Huang, Huang, Kwan, Antonia, Lin, Chi-Chung, Piccione, Emily C., Wei, Michael C., Yin, Shen, Barlett, Nancy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824395/
https://www.ncbi.nlm.nih.gov/pubmed/34914545
http://dx.doi.org/10.1200/JCO.21.00931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824395/
https://www.ncbi.nlm.nih.gov/pubmed/34914545
http://dx.doi.org/10.1200/JCO.21.00931

Ejemplares similares